New class of synthetic antibiotics set to tackle superbugs
Recce Pharmaceuticals is commercializing a novel synthetic broad-spectrum antibiotic designed to overcome antimicrobial resistance. Its lead compound, RECCE 327, is one of the first entirely new classes of antibiotics to be developed in more than 30 years.
No comments yet.